MCRA’s Cardio and Biocompatibility Regulatory teams are proud to have supported Xeltis with their IDE submission. #IDE #FDAapproval #FDAguidance #FDAsubmission #cardio #medtech #medicaldevices
Today, Xeltis announces that the FDA has approved an Investigational Device Exemption (IDE) submission to begin enrolling patients in a pivotal study for #aXess. This US-based pivotal trial follows strong 12-month data from a first-in-human study in Europe and marks a significant milestone in the company's clinical strategy. aXess is a restorative conduit that allows the formation of a new living vessel for hemodialysis vascular access, providing a better dialysis patient experience. To learn more about the aXess US pivotal trial, see the press release in the comments section below. #FDA #VascularAccess #IDE
Chief Executive Officer at USA and International Research Inc.
1wCongratulations on reaching this milestone! Looking forward to seeing the impact of your collaboration with Xeltis in the field of cardio innovation.